Get the Stockscreener App
10.85
0.37%
0.04
Pre-market:
10.57
-0.28
-2.58%
10 X Genomics Inc stock is traded at $10.85, with a volume of 2.39M.
It is up +0.37% in the last 24 hours and down -9.58% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
See More
Previous Close:
$10.81
Open:
$10.89
24h Volume:
2.39M
Relative Volume:
1.01
Market Cap:
$1.33B
Revenue:
$631.73M
Net Income/Loss:
$-239.78M
P/E Ratio:
-5.3713
EPS:
-2.02
Net Cash Flow:
$-33.45M
1W Performance:
-0.73%
1M Performance:
-9.58%
6M Performance:
-51.88%
1Y Performance:
-72.30%
1-Day Range:
$10.52
$10.98
1-Week Range:
$10.37
$11.79
52-Week Range:
$9.77
$39.70
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
10.85 | 1.33B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
233.46 | 37.90B | 2.75B | 714.14M | 1.09B | 4.33 |
|
SOLV
Solventum Corp
|
74.01 | 12.80B | 8.26B | 66.00M | 1.17B | 0.3682 |
|
DOCS
Doximity Inc
|
64.30 | 12.07B | 516.85M | 174.11M | 217.38M | 0.87 |
|
HQY
Healthequity Inc
|
95.78 | 8.30B | 1.15B | 96.70M | -161.99M | 1.09 |
|
TEM
Tempus Ai Inc
|
45.50 | 7.84B | 640.44M | -743.28M | -206.93M | -11.29 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-22-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-10-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Hold |
| May-01-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
Long Read Sequencing Market Top Companies Study10X Genomics, - openPR
Bruker motion backfires in US patent dispute with 10x Genomics, Harvard - MLex
10x Genomics IncOrdinary SharesClass A to Host Earnings Call - ACCESS Newswire
10x Genomics’ (TXG) Sell (E+) Rating Reiterated at Weiss Ratings - Defense World
Citigroup Issues Pessimistic Forecast for 10x Genomics (NASDAQ:TXG) Stock Price - Defense World
10x Genomics gets injunction against Parse Biosciences' ATAC Products - MSN
10x Genomics Dodges Appeal In DNA Analysis Patent Clash - Law 360 UK
10x genomics CEO Serge Saxonov sells $84,393 in stock By Investing.com - Investing.com Australia
Rhumbline Advisers Sells 1,641 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
10x genomics CEO Serge Saxonov sells $84,393 in stock - Investing.com
Sanctuary Advisors LLC Purchases 6,474 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
Short Interest in 10x Genomics, Inc. (NASDAQ:TXG) Expands By 34.4% - Defense World
10x Genomics Secures Injunction Against Parse Biosciences' Plann - GuruFocus.com
10x Genomics Secures Injunction Against Parse Biosciences’ Planned ATAC Products - The Malaysian Reserve
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products - Marketscreener.com
10x Genomics secures injunction against Parse Biosciences - Investing.com
10x Genomics gets injunction against Parse Biosciences' ATAC Products (TXG:NASDAQ) - Seeking Alpha
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products – Company Announcement - Financial Times
Patent Victory: How 10x Genomics Just Eliminated a Key Competitor in Genomic Analysis - StockTitan
10 Promising Biotech Stocks to Invest in (March 2025) - Securities.io
ARK Investment Management LLC Purchases 1,193,712 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
SVB Wealth LLC Acquires Shares of 522,609 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
Ieq Capital LLC Purchases 50,722 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
ING Groep NV Acquires New Shares in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics, Inc. (NASDAQ:TXG) CEO Sells $56,368.44 in Stock - MarketBeat
Director of 10x Genomics Picks Up 184% More Stock - Simply Wall St
Oxford Nanopore Expands Compatibility With 10x Genomics To Unlock Deeper Insights in Single-Cell Transcriptomics - Technology Networks
10x genomics’ president sells $50,602 in stock - Investing.com India
Insider Buying: 10x Genomics, Inc. (NASDAQ:TXG) Director Buys 40,000 Shares of Stock - MarketBeat
10x genomics CEO Serge Saxonov sells $56,346 in stock - Investing.com India
10x genomics CEO Serge Saxonov sells $56,346 in stock By Investing.com - Investing.com South Africa
10x genomics' president sells $50,602 in stock - Investing.com
10x genomics director Alan Mateo acquires $445,572 in stock - Investing.com
10x Genomics Director Mateo Alan Acquires 40,000 Shares - TradingView
Alberta Investment Management Corp Takes $3.21 Million Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, - GuruFocus.com
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis - Nasdaq
Can 10x Genomics' New 8-Million Cell Platform Transform Genomic Research? - StockTitan
Harvard, 10x Genomics Settle Patent Dispute With Vizgen - Harvard Crimson
10x Genomics, Inc. (NASDAQ:TXG) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
Weiss Ratings Reiterates Sell (E+) Rating for 10x Genomics (NASDAQ:TXG) - Defense World
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference - The Eastern Progress Online
10x Genomics, Inc. (NASDAQ:TXG) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Q1 EPS Estimates for 10x Genomics Lowered by Leerink Partnrs - MarketBeat
10x Genomics (NASDAQ:TXG) Lowered to "Hold" Rating by Leerink Partnrs - MarketBeat
10x Genomics (NASDAQ:TXG) Stock Price Up 8.3%Here's What Happened - MarketBeat
Citigroup Has Lowered Expectations for 10x Genomics (NASDAQ:TXG) Stock Price - MarketBeat
10x Genomics (NASDAQ:TXG) Price Target Cut to $12.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
10x Genomics' SWOT analysis: genomics firm faces NIH funding headwinds - Investing.com
10x Genomics (NASDAQ:TXG) Shares Gap Down on Disappointing Earnings - MarketBeat
Canaccord Genuity Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $18.00 - MarketBeat
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.01%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):